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A 13 year-old mixed-breed male dog was presented for a second opinion at the veterinary clinic 
with a tumor of approximately 15 cm3 on its abdomen. Fine-needle aspiration and cytological examination 
revealed moderately and distinctly displastic mesenchymal cells. Abdominal radiographs showed the extent 
of the tumor, which had developed mostly inside the abdomen. Radiography and CT revealed possible 
metastasis to the lungs. A diagnosis of malignant histiocytoma was made. The tumor was surgically removed 
at the owner’s request, but the dog died 5 days later. We follow with a case discussion, as well as the 
treatment and prognosis for this type of tumor. 
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Introduction 
The histiocytic sarcoma complex (HSC) is a group of neoplasms characterised by the 
proliferation of dendritic cells of either Langerhans cell or interstitial dendritic cells lineage that 
affects both dogs and cats, although the disease is more infrequent in cats (Klopfleisch R, 2016; 
Moore et al., 2006). Dog breeds more commonly affected by HS are the Bernese Mountain Dog, 
Flat-Coated Retriever, Rottweiler, Golden Retriever and perhaps miniature schnauzer (North S, 
Banks T, 2007; Lenz JA et al, 2017; Abadie et al, 2009). The HSC manifests under three forms: as 
localised lesions of single organs, as disseminated lesions in multiple organs or as hemophagocytic 
histiocytic sarcoma (HHC), a particular form arising from splenic macrophages (Withrow SJ et al., 
2013; Moore PF, 2014). 
The first form, called histiocytic sarcoma, is usually localised in the spleen, lymph nodes, 
lung, bone marrow, skin and subcutis, brain or the articular tissue of appendicular joints (Moore 
PF, 2014). It is composed of highly pleomorphic round cells, varying in cell and nucleus size and 
ratio (Withrow SJ et al., 2013). 
The second form, formerly designated as malignant histiocytoma (currently disseminated 
HS) occurs as more than one lesion in a single organ that rapidly spread to other locations (Moore 
PF, 2014). It has a more heterogenous appearance, comprising round, oval and spindle-shaped cells 
that are less pleomorphic but present more morphological features of malignancy (Withrow SJ et 
al., 2013; Moore PF, 2014). Other authors describe the disseminated form as the progression of the 
localised form beyond the regional lymph nodes, commonly to the lung, spleen, and lymph nodes 
(Klopfleisch R, 2016). 
The third form, hemophagocytic histiocytic sarcoma, is the most distinctive; it derives from 
splenic macrophages and localises in the spleen, liver, bone marrow, and lung (Klopfleisch R, 
2016). The cells are hard to differentiate from macrophages found in inflammatory lesions, as they 
can present little to no malignancy features and it clinically manifests as a hemolytic anemia that 





Neoplastic structure, HE, 400x - 
Abundant neoplastic cells with marked 
pleomorphism. Source: prepared by the 
authors 
Neoplastic structure, HE, 1000x - 
Mesenchymal cells with a malignant 
morphology - multinucleated cancer 
cells. Source: prepared by the authors. 
Neoplastic structure, HE, 1000x - 
Mesenchymal neoplastic cells: marked 
anisokaryosis, euchromatic nuclei, 
evidently nucleolated nuclei, atypical 
mitoses. Source: prepared by the 
authors. 
Figures 1-3. Histologic aspects of Gimmi’s histiocytic sarcoma. Source: prepared by 
dr. Teodoru Soare. 
 
Localised and disseminated HS present as white masses with a smooth cut surface, but they 
can also present red mottling (due to hemorrhage and necrosis), usually with distinct and 
uncapsulated margins, and differentiate from the hemophagocytic variant, which appears as a 
diffuse infiltrate in the affected organs (Meuten DJ, 2016; Klopfleisch R, 2016). 
Clinical signs depend on the affected organ(s), but are generally non-specific (anorexia, 
lethargy, malaise, weight loss) (Klopfleisch R, 2016). The mass effect of internal tumors can 
generate signs from unaffected organs (Klopfleisch R, 2016). Paraclinic findings might include a 
mild anemia (HS, diffuse HS) or a severe anemia (HHC), thrombocytopenia, hypoalbuminemia 
and rarely neutrophilia, hypercalcemia or hyper-gammaglobulinemia (Klopfleisch R, 2016, Argyle 
DJ et al, 2008). As hyperferritinemia seems to be common in dogs with HS, ferritin may be a useful 
serum biomarker for this neoplasm (Friedrichs et al, 2010). 
Treatment options are wide surgical excision and chemotherapy (Meuten DJ, 2016, 
Klopfleisch R, 2016). The localised form is curable with surgery, if the lesion is detected early; 
once the disease spreads the treatment is palliative chemotherapy (Meuten DJ, 2016). 
Chemotherapy for disseminated HS with lomustine, an alkylating agent, at 60–90 mg/m2 may 
prolong survival times in responsive dogs (Klopfleisch R, 2016; Skorupski KA et al, 2007; North 
S and Banks T, 2007). Epirubicin, dacarbazine and other substances can be used in dogs that do 
not respond to lomustine with variable results (Mason SL, 2017; Kezen KA, 2017, Moore AS, 
2017). The prognosis is poor for all forms except localised HS (Klopfleisch R, 2016, Meuten DJ, 
2016; Dervisis NG, 2016; Moore AS, 2017). 
There is a report on the successful treatment of 4 cases of canine disseminated HS with the 
human major histocompatibility complex nonrestricted cytotoxic T-cell line TALL-1041 
(Vissoneau S et al, 1997), but this is option is not currently widely available. 
 
Materials and Methods 
Complete blood counts were performed in-house using a Mindray BC-2800 Vet automatic 
hematology analyzer. Blood biochemistry was performed in-house using a Rayto RT-1904C 
semiautomatic chemistry analyzer. Cytology and histopathology were performed Dr. Teodoru 
Soare at the Faculty of Veterinary Medicine Bucharest. The radiologic and CT examinations were 
performed by dr. Florin Grosu at 4VET Radiology Center. The ultrasonographic examinations 






A 13 year-old medium-sized mixed-breed male dog was presented for a second opinion at 
the veterinary clinic for a large tumor on it abdomen (figure 4). The dog had been neutered at the 
age of 2. The tumor was extremely large (approximately 15 cm3) and had already invaded the 
abdomen, making the point of origin impossible to discern. Ghimi manifested an intermittent fever, 
having evening episodes of pyrexia with a body temperature oscillating between 40-42ºC, 
registering an optimal temperature during the day). The dog also presented with vomit during the 
febrile periods and a loose stool the next morning. Ghimi had inspiratory dyspnea, in his attempt 
to compensate with prolonged, deep inspirations. The body condition score was 2/5 (AAHA Body 
Condition Scoring Systems, 2010). 
 
Figure 4. Preoperative aspect of the tumor. Source: from the authors. 
 
Palpation of the abdomen was impossible due to the extent of the growth. The superficial 
lymph nodes (popliteal, axillary and prescapular) were reactive; the reactivity of the submandibular 
lymph nodes could have also been due to the presence of advanced periodontal disease and 
infection. At this point, the dog was not eating and received supportive treatment (iv fluids, 
aminoacids), iv broad-spectrum antibiotics (ceftriaxone), pain medication (tramadol) and 
corticosteroids. 
A CBC revealed a leukemoid reaction, as a physiological response to stress and infection 
(WBC 100.9 - reference values 6-17 K/μL), with mild lymphocytosis and intense neutrophilia, a 
decreased RBC count (3.64, reference 5.5-8.5 M/μL) and hematocrit (26.8 reference 39-56%) with 
increased hemoglobin (24, reference 11-19 g/dL). Blood biochemistry was unremarkable except 
for the alkaline phosphatase (1114.17, reference 10.6-100.7 U/L) and serum amylase (3965.84, 
reference 269.5-1462.4 U/L). By the second day of ceftriaxone and hydrocortisone hemisuccinate 
the dog improved, with the disappearance of the digestive signs and the improvement of the 
respiratory effort. Ultrasound identified a soft tissue mass of variable echogenicity due to areas of 
necrosis and mineralization. 
Two ultrasound guided fine needle aspirates were evaluated cytologically, but due to the 
presence of inflammatory cells and necrotic debris, they were deemed inconclusive. They did, 
however, reveal a few moderately and distinctly displastic mesenchymal cells alongside red blood 
cells, neutrophils, macrophages and lymphocytes. A decision was taken to further investigate the 
patient in order to establish a conclusive diagnostic. 
In order to evaluate the extent of the tumor and to identify the presence of any metastases, 
Ghimi was referred for thoracic and abdominal radiography. The radiographs revealed 




tumor, which displaced the stomach, lung and intestines. The radiologic appearance of the tumor 
was of a macronodular densification of soft tissue with areas of amorphous calcification at the right 
thoraco-abdominal junction of approximately 14 cm/19 cm (figures 6-7). 
 
Figures 5-7. Ghimi’s thoracic (left) and abdominal (center, right) radiographs. Note the presence of 
nodular lesions in the lung, probably lung metastases and the gross displacement of the organs in the 
abdominal cavity. 
Images courtesy of dr. Grosu Florin, 4Vet Radiology Center, Bucharest 
 
 
At the owner’s insistence that the animal be operated and the tumor removed the dog was 
again reffered for computerized tomography. The surgeon agreed to palliative surgery to remove 





The CT examination described a heterogenous soft-tissue tumor (figures 7-8, 11-12) 
located in the cranial and ventral mid-abdomen, with relatively well delineated margins of 
approximately 20 cm*13 cm*18 cm (L*H*D). The growth has a significant mass effect over the 
surrounding organs (spleen, liver, gallbladder, small intestine and colon. Its heterogenicity was due 
to hypoattenuation probably caused by areas of hemmorhagic fluid or necrosis, but also to areas of 
mineralization/calcification. The tumor filled moderately and irregularly with contrast, which 
permitted the identification of the tumor’s origin to the right ventro-lateral abdominal wall. Its 
growth had remodelled the orientation of the floating ribs, whose distal half became horizontal. 
Both lungs presented micro and macro intestitial nodules (figure 10). On the head of the spleen 
there was a hypoacoustic area of 1.5-2 cm in diameter (figure 9) that did not fill up with contrast 
(another possible metastasis). 
Before the surgery, blood biochemistry revealed an improvement in serum biochemical 
parameters: serum amylase decreased to half of its initial value and alkaline phosphatase decreased 
slightly, with the exception of urea, which doubled to 75.75 mg/dL (reference 8.8-25.9 mg/dL). 
CBC showed continous lymphocytosis (to half the initial value), an increased RBC count and 
hematocrit with decreased hemoglobin. 
According to the owner’s wishes, the team proceeded with the surgical excision, despite 
being warned of the grave prognosis and the small chances of long-term survival. The tumor was 
removed successfully (figures 12-15), but the dog evolved well for two days but on day three he 
decompensated (respiratory and circulatory decompensation) and died five days avter the 
intervention. A histopathologic analysis confirmed the suspicion of histiocytic sarcoma. 
 
Figures 10-13. Intraoperative aspects. Source: from the authors. 
 
Conclusions 
Due to the extent of the disease, in Ghimi’s case treatment was illusory. Currently, HS is 
only curable before it metastasises through wide surgical excision. But for the owner’s insistence 
for sugery, the correct approach would have been to treat with palliative chemotherapy. A tumor 
this size and with such a compressive effect was not well suited for palliative surgery, as the dog 
decompensated and subsequently died. We recommend that any growth should be investigated as 
soon as it is detected and ideally, yearly check-ups should include abdominal ultrasonography. 
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